BZW1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the BZW1 gene. BZW1 encodes a translation initiation factor that promotes mRNA recruitment to ribosomes, and its disruption using CRISPR/Cas9-mediated gene targeting generates a heterogeneous pool of edited cells. This polyclonal format preserves the natural distribution of editing outcomes, representing a robust model for population-level analyses of gene function without single-cell cloning bias.
The host cell line HAP1 is a near-haploid human cell line derived from the chronic myeloid leukemia line KBM-7. HAP1 cells exhibit an adherent fibroblast-like morphology and possess a haploid genome, which simplifies knockout generation because a single targeting event suffices to eliminate gene function. This haploid background avoids dominant effects from unmodified alleles and is widely employed in CRISPR-Cas9-based genetic screens and functional genomics, making it a powerful platform for dissecting gene regulatory networks in a cancer-relevant context.
BZW1 functions as a translation initiation factor that facilitates recruitment of mRNAs with structured 5′ untranslated regions to the ribosome. It acts downstream of the mTORC1 kinase, which integrates growth factor and amino acid signals. mTORC1 phosphorylates S6K and 4E-BP1 to enhance translation initiation. BZW1 interacts with the eIF3 complex, the 40S ribosomal subunit, eIF2, and eIF4G, thereby bridging pre-initiation complex assembly. Knockout of BZW1 impairs this bridging, selectively diminishing translation of mRNAs encoding cell cycle regulators and ribosomal proteins, reducing cell proliferation and survival.
In HAP1 cells, which retain the characteristics of their leukemic origin, BZW1 knockout provides a physiologically relevant model to examine how translation initiation dysregulation contributes to oncogenesis. Because the haploid genome ensures unambiguous genotype-phenotype correlations, this model is particularly suited for studying the role of mTORC1-driven translation in leukemia and solid tumors with aberrant protein synthesis. The loss of BZW1 disrupts the production of growth-promoting proteins, revealing critical dependencies that may be exploited therapeutically.
This polyclonal knockout cell product supports a wide range of experimental applications, including functional characterization of translation regulation, cancer biology studies, and genetic interaction screens. Representative assays include western blotting to confirm target protein loss, RT-qPCR for transcript-level analysis, polysome profiling to assess ribosome loading, puromycin incorporation assays to measure global protein synthesis, and flow cytometry for cell cycle distribution. For additional information or technical support, please contact Ascent Research.
